Starboard Value · conference-presentation
Pfizer Inc. (PFE)
74 pages · 3 arc beats · 3 loops
Pfizer Inc. (PFE)
Starboard Value · 2024-10 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
151015202530354045505560657074
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 34 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 8 hits — 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Agitate (Make it worse) 21 slides 100% 21/21 slides 100% 21/21 slides · 140 hits — 0/21 slides
4.8% 1/21 slides 71.4% 15/21 slides 100% 21/21 slides 100% 21/21 slides · 42 hits Solution (Provide relief) 12 slides 100% 12/12 slides 100% 12/12 slides · 76 hits — 0/12 slides
— 0/12 slides
100% 12/12 slides 100% 12/12 slides 100% 12/12 slides · 34 hits Slide inventory
74 every slide · same image gating as the playbook
03
The slide uses a three-column layout to segment the portfolio. The bottom callout emphasizes the societal impact.summarize
05
The slide uses a dual-axis chart to visually suggest a causal link between vaccine rollout and reduced mortality.establish_context
06
The chart uses a visual annotation to highlight the incremental FCF in 2021 and 2022 relative to the 2020 baseline.analyze_data
07
The chart uses a red vertical arrow to explicitly quantify the 132-point underperformance gap.expose_gap
08
The chart uses a custom bridge structure to calculate total value lost.show_valuation_bridge
09
The chart highlights LLY and NVO as outliers due to GLP-1 participation. Pfizer is shown at 10x, below the 14x peer median.compare_peers
10
The slide uses a structured list of four key problem areas (A, B, C, D) followed by a summary of the financial impact.diagnose_problem
12
The chart highlights Pfizer's position relative to a peer median of 46 drugs.compare_peers
13
The slide uses external validation to support a thesis about the company's strategic positioning.cite_precedent
14
This slide is part of an activist investor presentation (Starboard Value) intended to expose management's past claims against current performance or strategy.expose_contradiction
15
The slide uses a dialogue format between a GS Analyst and the CEO to highlight a specific strategic commitment.expose_contradiction
16
The slide uses a historical Pfizer graphic to frame a critique of R&D productivity.expose_contradiction
17
The slide uses a table to demonstrate historical management commitments to specific R&D milestones.cite_precedent
18
The slide uses a screenshot of a Pfizer table to critique their 'Up to 15 in 5' program claims.expose_contradiction
19
The slide uses a screenshot of a Pfizer investor presentation to frame the argument that management failed to deliver on its own stated goals.expose_contradiction
20
The slide uses a callout to emphasize the gap between actual performance and the blockbuster threshold, and includes a quote from a 10-K filing to support the dexpose_contradiction
21
The slide uses a screenshot of a news article as evidence of a failed clinical trial.cite_precedent
22
The slide uses a red double-headed arrow to emphasize the gap between the 2030 projection and the blockbuster threshold.analyze_data
23
The slide uses a visual gap analysis to emphasize the shortfall against a market benchmark.analyze_data
24
The slide uses a highlighted excerpt from a third-party report to substantiate the claim of failure.expose_contradiction
25
The slide uses a direct quote/excerpt from a primary source to validate the claim of continued success.cite_precedent
26
The slide uses a series of callout boxes to present external validation of competitive pressure.preempt_rebuttal
27
The slide uses a direct citation from a company press release to establish a negative precedent or track record.cite_precedent
28
The slide uses a screenshot of a press release to establish historical context for the drug's success.cite_precedent
29
The slide uses a screenshot of a news article to provide external validation of a failed drug development program.cite_precedent
30
The slide uses a dialogue format between an analyst and the CEO to frame the company's strategic priorities.cite_precedent
31
The slide uses a 'preempt_rebuttal' or 'expose_contradiction' strategy by showing original company claims and implying failure through the context of the activiexpose_contradiction
32
Uses highlighted text within quotes to emphasize key claims.cite_precedent
Open slide detailLoop · Cost Of Inaction
33
The slide highlights the gap between internal management targets and external analyst consensus.analyze_data
Open slide detailLoop · Cost Of Inaction
34
Uses external analyst quotes to build a case against management's R&D execution.name_villain
Open slide detailLoop · Cost Of Inaction
35
The chart highlights a 66% decrease in analyst expectations between March 2023 and October 2024.analyze_data
Open slide detailLoop · Cost Of Inaction
36
The slide uses a grouped bar chart to contrast the revenue growth trajectories of two key competitors in the GLP-1 space.compare_peers
Open slide detailLoop · Cost Of Inaction
38
The chart highlights Pfizer's underperformance relative to peers, with a specific callout for 'PFE Excl. COVID'.compare_peers
Open slide detailLoop · Cost Of Inaction
39
The chart highlights that even when excluding COVID-related revenue, Pfizer (PFE) and PFE Excl. COVID underperform the peer median.compare_peers
Open slide detailLoop · Cost Of Inaction
40
The chart uses a broken axis for the top two performers (NVO, LLY) to accommodate the scale.compare_peers
Open slide detailLoop · Cost Of Inaction
42
The slide uses a bracket to aggregate the total M&A spend.analyze_data
Open slide detailLoop · Cost Of Inaction
43
The slide uses a stacked bar chart to visualize the revenue gap and contribution from various acquisitions.expose_contradiction
Open slide detailLoop · Cost Of Inaction
44
The chart highlights the 3.3x multiple for 'PFE Consolidated Deals (Mgmt)' as an outlier compared to the 10-year median of 2.4x.analyze_data
Open slide detailLoop · Cost Of Inaction
45
The chart uses a stacked bar format to break down the revenue contributions from specific acquisitions (Seagen, Biohaven, GBT, Arena, ReViral).expose_gap
Open slide detailLoop · Cost Of Inaction
46
The chart highlights two specific Pfizer deal data points (3.3x and 5.1x) against a 10-year industry median of 2.4x.analyze_data
Open slide detailLoop · Cost Of Inaction
47
The slide uses a bar chart to visualize the delta between historical transaction multiples and current market valuation multiples.show_valuation_bridge
Open slide detailLoop · Cost Of Inaction
48
The slide uses red annotations and arrows to draw a comparison between the acquisition cost and the projected revenue, framing it as a poor investment decision.expose_contradiction
Open slide detailLoop · Cost Of Inaction
49
The slide uses a direct quote from a press release to substantiate the claim of product withdrawal.expose_contradiction
Open slide detailLoop · Cost Of Inaction
50
The slide uses external analyst sentiment to frame Pfizer's acquisition strategy as flawed.expose_contradiction
Open slide detailLoop · Cost Of Inaction
52
The slide uses a red dashed box to isolate the 'COVID Benefit' period and another to highlight the summary statistics.expose_contradiction
Open slide detailLoop · Cost Of Inaction
53
The chart uses red bars to highlight Pfizer (PFE) and its 'Excl. COVID' performance, contrasting them with the blue bars of its peers.compare_peers
Open slide detailLoop · Cost Of Inaction
54
The slide uses red 'X' marks to visually emphasize the failure to meet expectations.expose_contradiction
Open slide detailLoop · Cost Of Inaction
55
The slide uses a bar chart to contrast historical performance with management's 2023 guidance, implying the guidance is overly optimistic given inventory levelsexpose_contradiction
Open slide detailLoop · Cost Of Inaction
56
The slide uses a visual comparison of 'Doses Sold' vs 'Doses Used' to illustrate inventory dynamics and management's optimistic outlook.expose_contradiction
Open slide detailLoop · Cost Of Inaction
57
The slide uses a red-blue contrast to emphasize the negative performance gap.expose_contradiction
Open slide detailLoop · Cost Of Inaction
58
Uses red arrows to visually emphasize the gap between guidance and actuals, and the subsequent decline.expose_contradiction
Open slide detailLoop · Cost Of Inaction
59
The slide uses a waterfall-style gap visualization to emphasize the delta between market expectations and company guidance.diagnose_problem
Open slide detailLoop · Cost Of Inaction
60
The slide uses quotes from Wolfe, JP Morgan, and TD Cowen to build a case against management.expose_contradiction
Open slide detailLoop · Cost Of Inaction
62
The slide uses a quote-based argument to align the activist investor's thesis with management's stated goals.cite_precedent
63
The chart uses a visual callout to quantify the 132 percentage point gap between Pfizer and the S&P 500.expose_gap
64
The slide uses a table from Pfizer's own Q1-2019 presentation to point out programs marked with 'X' (discontinued) or other delays, framing them as evidence of expose_contradiction
66
The chart highlights Pfizer (PFE) in red, showing it has the lowest return among the peer group.compare_peers
67
Uses a simple division framework to highlight capital allocation inefficiency.expose_gap
68
The slide uses a waterfall bridge to argue that current management's projected revenue return (15%) is insufficient compared to the target (38%).show_valuation_bridge
69
Uses a waterfall-style logic to derive an incremental revenue requirement of $29 billion.quantify_opportunity
70
The chart uses a waterfall bridge format to show the impact of LOEs and growth on 2030 revenue projections.show_valuation_bridge
71
Includes a causal flow diagram showing the link between achieving a 38% return and specific 2030 financial outcomes.diagnose_problem
72
This is a classic activist investor slide calling for board intervention in capital allocation.state_demand
73
The chart highlights Pfizer's valuation gap relative to peers, suggesting undervaluation.compare_peers